pharmaphorum13m
FDA expands label for Roche's eye disease implant Susvimo
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
TMCnet56m
e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
Title: Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B Format: Oral Presentation Presentation Number: OR10 Date: 7 th February 2025 Session: SLAM e-therapeutics plc ("ETX") ...
e-therapeutics plc: e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will p ...
DURAVYU shows promise in Phase 2 trial for eye disease
WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...